secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001213900-24-003000
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics CMO Cedric O'Gorman departs; separation agreement includes $414,500 payment
--------------------------------------------------------------------------------

- Dr. Cedric O'Gorman's service as Chief Medical Officer ended January 3, 2024, by mutual agreement.
- Separation agreement provides $414,500 payment and six months of COBRA premium coverage.
- O'Gorman may exercise vested stock options under the 2021 Equity Incentive Plan until March 3, 2024, via cashless exercise.
- Agreement includes confidentiality, release, and non-disparagement provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024003000/0001213900-24-003000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024003000/ea191520-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-003000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer